TrialSignal transduction and targeted therapy2026

Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.

Zhigang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.